Overview

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

Status:
Terminated
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.
Phase:
Phase 2
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc